Ohio regulators have moved to ban certain kratom derivatives, including highly concentrated products containing 7-hydroxymitragynine, citing health and safety concerns. The Ohio Board of Pharmacy adopted an emergency rule that makes it illegal to sell or possess these products while permanent regulations are developed.

Kratom is derived from a tropical plant and can have stimulant effects at low doses and opioid-like effects at higher doses. Safety experts warn that concentrated forms may impair judgment, reaction time and motor skills. Standard workplace drug tests typically do not detect kratom, creating potential challenges for employers in safety-sensitive environments.

Ohio manufacturers are encouraged to monitor regulatory developments and review workplace safety and substance-use policies to address emerging risks that could affect employee safety and operations. 12/16/2025